CTOs on the Move


 
Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Microbion raised $25M on 01/06/2017
Microbion raised $17.1M on 05/28/2020

Similar Companies

Emerald Scientific

Emerald Scientific is a leading supplier of high quality reagents, supplies, equipment, and services to analytical laboratories. Our staff has decades of scientific expertise, and we’re here to help our customers grow while meeting the latest regulatory requirements and making the best decisions for product quality and safety.

Cetac Technologies

Cetac Technologies is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RDMD

RDMD`s mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.

Sartorius Stedim Biotech

Sartorius Stedim Biotech is a Napa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alveo Technologies

At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo`s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens that threaten public health, across all modalities. We believe increased access to real-time test results will transform the way individuals, healthcare providers and public health professionals identify and manage infectious diseases. With be.well™, we will Know Sooner, Act Faster™.